Search

Now showing items 1-3 of 3

Efficacy and safety of FOLFIRI/aflibercept in second-line treatment of metastatic colorectal cancer in a real-world population: Prognostic and predictive markers

2019- Fernández Montes, Ana; Martinez Lago, Nieves Purificacion; Covela Rúa, Marta; De La Cámara Gómez, Juan Cruz; González Villaroel, Paula; [et al.]

Efficacy and safety of FOLFIRI/Aflibercept (FA) in an elderly population with metastatic colorectal cancer (mCRC) after the failure of an oxaliplatin-based regimen

2019- Martinez Lago, Nieves Purificacion; Carmona Campos, Marta; Gonzalez Villarroel, P; Salgado Fernández, Mercedes; De La Cámara Gómez, Juan Cruz; [et al.]

FOLFIRI plus panitumumab as second-line treatment in mutated RAS metastatic colorectal cancer patients who converted to wild type RAS after receiving first-line FOLFOX/CAPOX plus bevacizumab-based treatment: Phase II CONVERTIX trial

2019- Fernández Montes, Ana; Martinez Lago, Nieves Purificacion; De La Cámara Gómez, Juan Cruz; Covela Rúa, Marta; Cousillas Castiñeiras, A; [et al.]